SN Gene Lab

Strengthening Laboratory Genomic Sequencing Capacity

Samridh support

The blended finance structure designed by SAMRIDH enabled SN Gene to avail a loan from a banking institution to meet 70% of the capital expenditure. The balance 30% was funded through internal accruals. Further, SAMRIDH’s support in the form of performance-linked payments is helping the entity in meeting the operating expenditure in the initial phase of the project ensuring it achieves financial sustainability. Moreover, the next-generation sequencing (NGS) facility created with SAMRIDH’s support can be used for a variety of pathogen tests, which will make it possible for SN Gene to expand its business offerings and achieve long-term sustainability.

Geographical Focus
  • PAN India
Potential Impact
  • 60%

    reduction in
    the cost of sequencing

The biggest challenge India faced during the COVID-19 pandemic, and more specifically during the catastrophic second wave caused by the Delta variant, was the inability to carry out genomic sequencing of the coronavirus. As on September 2, 2021, India had sequenced a meagre 0.2 percent of its cumulative cases even though the government had set a target of 5% of positive samples to be sequenced. Due to the sub-par capacity to test adequately and identify new virus strains, timely assessment of the transmissibility, and pathogenicity of the Delta variant could not be understood.

The new sequencing system developed by SN Gene Lab provides an effective solution to identify new coronavirus strains and other novel pathogens, support in tracking the transmission routes of the virus globally, and detect mutations quickly. These capabilities can support in preventing the spread of new strain types, identifying viral mutations that can avoid detection by established molecular diagnostic assays and can affect vaccine potency, and in screening targets for possible COVID-19 therapeutics. They can also help in identifying and characterizing respiratory co-infections and antimicrobial resistance.